Hospitalization Rate of Respiratory Syncytial Virus associated Acute Lower Respiratory Infection among Young Children in Suzhou, China, 2010-2014

Background: Data on disease burden of respiratory syncytial virus (RSV) associated acute lower respiratory infection (ALRI) among young children are limited in China. This study aimed to estimate the hospitalization rate of RSV-associated ALRI (RSV-ALRI) among children aged 0~59 months in Suzhou, China. Methods: We retrospectively identified all hospitalized ALRI children aged 0~59 months in Suzhou University Affiliated Children’s Hospital during January 2010 to December 2014. Detailed diagnosis and treatment data were collected by individual medical chart review. Referring to WHO influenza disease burden estimation method, we estimated the hospitalization rate of RSV-ALRI among children aged 0~59 months in Suzhou, China. Results: Among 28,209 ALRI cases, 19,317 (68.5%) were tested for RSV and the RSV positive proportion was 21.3% (4,107/19,317). The average hospitalization rate of RSV-ALRI for children aged 0~59 months was 14 (95% confidence interval [CI]:14~14)/1,000 children-years, for children aged 0~5, 6~11, 12~23, and 24~59 months were 70 (95%CI: 67~73), 31 (95%CI: 29~33), 11 (95%CI: 10~12), and 3 (95%CI: 3~3) /1,000 children-years, respectively. Conclusion: There is considerable RSV-ALRI hospitalization among children aged 0~59 months, particularly among children aged <1 years. An effective monoclonal antibody or vaccine is urgently needed to address the substantial hospitalization burden owing to RSV infection. Key words: Respiratory syncytial virus, Hospitalization rate, Acute lower respiratory infection, Children, China

Download Full-text

Hospitalization rate of respiratory syncytial virus‐associated acute lower respiratory infection among young children in Suzhou, China, 2010–2014

Influenza and Other Respiratory Viruses ◽

10.1111/irv.12958 ◽

2022 ◽

Author(s):

Shaolong Ren ◽

Ting Shi ◽

Wei Shan ◽

Si Shen ◽

Qinghui Chen ◽

...

Keyword(s):

Respiratory Syncytial Virus ◽

Young Children ◽

Respiratory Infection ◽

Hospitalization Rate ◽

Acute Lower Respiratory Infection ◽

Lower Respiratory Infection ◽

Syncytial Virus

Download Full-text

Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis

The Journal of Infectious Diseases ◽

10.1093/infdis/jiz683 ◽

2020 ◽

Vol 222 (Supplement_7) ◽

pp. S680-S687 ◽

Cited By ~ 3

Author(s):

Shanshan Zhang ◽

Lily Zainal Akmar ◽

Freddie Bailey ◽

Barbara A Rath ◽

Maren Alchikh ◽

...

Keyword(s):

Respiratory Syncytial Virus ◽

Young Children ◽

Respiratory Infection ◽

Meta Analysis ◽

Acute Lower Respiratory Infection ◽

Lower Respiratory Infection ◽

Initial Event ◽

Global Cost ◽

Syncytial Virus

Abstract Background Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection (ALRI) in young children aged <5 years. Methods We aimed to identify the global inpatient and outpatient cost of management of RSV-ALRI in young children to assist health policy makers in making decisions related to resource allocation for interventions to reduce severe morbidity and mortality from RSV in this age group. We searched 3 electronic databases including Global Health, Medline, and EMBASE for studies reporting cost data on RSV management in children under 60 months from 2000 to 2017. Unpublished data on the management cost of RSV episodes were collected through collaboration with an international working group (RSV GEN) and claim databases. Results We identified 41 studies reporting data from year 1987 to 2017, mainly from Europe, North America, and Australia, covering the management of a total of 365 828 RSV disease episodes. The average cost per episode was €3452 (95% confidence interval [CI], 3265–3639) and €299 (95% CI, 295–303) for inpatient and outpatient management without follow-up, and it increased to €8591(95% CI, 8489–8692) and €2191 (95% CI, 2190–2192), respectively, with follow-up to 2 years after the initial event. Conclusions Known risk factors (early and late preterm birth, congenital heart disease, chronic lung disease, intensive care unit admission, and ventilator use) were associated with €4160 (95% CI, 3237–5082) increased cost of hospitalization. The global cost of inpatient and outpatient RSV ALRI management in young children in 2017 was estimated to be approximately €4.82 billion (95% CI, 3.47–7.93), 65% of these in developing countries and 55% of global costs accounted for by hospitalization. We have demonstrated that RSV imposed a substantial economic burden on health systems, governments, and the society.

Download Full-text